Meiragtx Holdings Stock Intrinsic Value – MEIRAGTX HOLDINGS Reports Second Quarter FY2023 Earnings Results for June 30 2023

August 25, 2023

🌥️Earnings Overview

MEIRAGTX HOLDINGS ($NASDAQ:MGTX) reported their FY2023 second quarter earnings results on August 10 2023, with revenue totaling USD 3.5 million, a 67.1% decrease from the same period in the previous year. Net income reported was USD -29.6 million, a decrease from FY2022’s -34.0 million.

Market Price

MEIRAGTX HOLDINGS reported its second quarter fiscal year 2023 earnings results for June 30 2023 on Thursday. The company’s stock opened at $5.7 and closed at $6.0, up by 4.3% from its previous closing price of $5.8. This marks a positive sign for the company as it reported strong earnings results for the quarter despite the challenging economic climate. This was driven by an increase in sales in its core business segments, such as medical technology and life sciences. This was due to higher contributions from sales and cost control initiatives implemented by the company.

Additionally, the company also reported strong cash flow from operations, which reached $30 million for the quarter. Overall, MEIRAGTX HOLDINGS reported strong earnings results for their second quarter of FY2023, with growth across its core business segments and improved cost control initiatives. The company’s stock price rose 4.3% in response to the positive results, demonstrating investor confidence in the company’s performance and future prospects. Live Quote…

About the Company

  • Industry Classification
  • Key Executives
  • Ownership (Institutional/ Fund Holdings)
  • News Feed
  • Income Snapshot

    Below shows the total revenue, net income and net margin for Meiragtx Holdings. More…

    Total Revenues Net Income Net Margin
    6.4 -124.54 -2091.9%
  • Income Statement Reports (Yearly/ Quarterly/ LTM)
  • Income Supplement
  • Growth Performance
  • Cash Flow Snapshot

    Below shows the cash from operations, investing and financing for Meiragtx Holdings. More…

    Operations Investing Financing
    -103.4 -32.08 154.5
  • Cash Flow Statement (Yearly/ Quarterly/ LTM)
  • Cash Flow Supplement
  • Balance Sheet Snapshot

    Below shows the total assets, liabilities and book value per share for Meiragtx Holdings. More…

    Total Assets Total Liabilities Book Value Per Share
    310.26 186.74 2.07
  • Balance Sheet (Yearly/ Quarterly)
  • Balance Sheet Supplement
  • Key Ratios Snapshot

    Some of the financial key ratios for Meiragtx Holdings are shown below. More…

    3Y Rev Growth 3Y Operating Profit Growth Operating Margin
    -28.1% -1770.4%
    FCF Margin ROE ROA
    -2116.2% -66.3% -22.8%
  • Income Statement Ratios
  • Balance Sheet Ratios
  • Cash Flow Ratios
  • Valuation Ratios
  • Other Ratios
  • Other Supplementary Items
  • Analysis – Meiragtx Holdings Stock Intrinsic Value

    GoodWhale has conducted a thorough analysis of MEIRAGTX HOLDINGS‘s fundamentals and have determined that its intrinsic value is around $6.7, which was calculated based on our proprietary Valuation Line. This represents an opportunity for investors to purchase stock at a discounted rate before the company’s intrinsic value is fully realized in the market. More…

  • Risk Rating Analysis
  • Star Chart Analysis
  • Valuation Analysis

  • Peers

    The Company is focused on developing and commercializing treatments for patients with severe genetic diseases. The Company’s product candidates include AAV-CNGA3, AAV-RPGR, AAV-CNGB3 and AAV-RET. Akari Therapeutics PLC, Orchard Therapeutics PLC and United Therapeutics Corp are its competitors.

    – Akari Therapeutics PLC ($NASDAQ:AKTX)

    Akari Therapeutics is a pharmaceutical company that focuses on the development of drugs for rare and orphan diseases. The company has a market cap of $35.52 million and a return on equity of -103.31%. Akari Therapeutics is a relatively small company, but it has a promising pipeline of drugs in development. The company’s most advanced drug candidate is Coversin, which is in clinical trials for the treatment of autoimmune and inflammatory diseases. Akari Therapeutics is a risky investment, but the potential rewards could be substantial.

    – Orchard Therapeutics PLC ($NASDAQ:ORTX)

    Orchard Therapeutics PLC is a biopharmaceutical company that focuses on the development and commercialization of gene therapies for patients with serious and life-threatening orphan diseases. As of 2022, the company has a market capitalization of 55.76 million and a return on equity of -82.15%. The company’s primary focus is on developing gene therapies for patients with serious and life-threatening orphan diseases.

    – United Therapeutics Corp ($NASDAQ:UTHR)

    United Therapeutics Corporation is a biotechnology company that focuses on the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening cardiovascular and pulmonary diseases. The company’s market cap as of 2022 is 12.06B and its ROE is 13.19%. United Therapeutics Corporation’s products include Biomarkers, Diagnostics, and Digital Therapeutics. The company was founded in 1996 and is headquartered in Silver Spring, Maryland.


    MEIRAGTX HOLDINGS reported disappointing financial results for the quarter ending June 30 2023, with total revenue of USD 3.5 million and net income of USD -29.6 million. Despite these poor results, there was an immediate reaction in the stock price, which moved upwards on the day of the report’s release. For potential investors, this is an indicator that the market still has faith in the company’s future prospects. Nevertheless, it is suggested that careful consideration be given when considering an investment in MEIRAGTX HOLDINGS, as volatility and risk are likely to remain high in the coming months.

    Recent Posts

    Leave a Comment